Introduction/Background To evaluate the long-term results of patient treatment with endometrial cancer older than 70 years compared with younger patients.

Methodology The data of 309 patients with endometrial cancer who received primary surgical treatment in the N.N. Petrov Research Institute of Oncology from 2009 to 2016 were divided into two groups: Group 1-≥70 years (the main group, n=159), Group 2-50-69 years (the control group, n=150).

Results In the 1st group, a non-endometrioid tumor histotype was more common-17.61% versus 4.67% in the 2nd group (p<0.001), common (III–IV) stages of the disease-17.61% against 6.67% respectively (p=0.003). The average observation time in the 1st group was 35.7±30.3 months, in the 2nd group-43.8±31.2 months. Recurrence rate was recorded in 23.36% in the 1st group and 13% in the 2nd group (p<0.05). The average time of progression in the 1st group was 14.7±16.6 months, in the 2nd group 15.5±13.5 months (p>0.05). In the group of 50–69 years, in most cases, distant metastases were recorded - 46.15% (bones, lungs, supraclavicular lymph nodes, pancreas) versus 18.75% in the group ≥70 years (p>0.05). In the 1st group the leading variant of the progression of the disease was local recurrence (vaginal stump) - 46.88% against 23.08% in the 2nd group, p>0.05. The overall survival of patients in the group of ≥70 years was 84% against 98% in the group of 50–69 years (p<0.01), the relapse-free survival rate was 81% and 89% in the 2nd and 1st groups, respectively (p<0,05).

Conclusion Endometrial cancer in the group ≥70 years is more aggressive from the point of view of the histological type of tumor, the stage of the disease at the time of diagnosis is characterized by a poor prognosis.

Disclosure Nothing to disclose.